Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: Pooled analysis of 2 consecutive trials

Francesco Boccardo, Alessandra Rubagotti, Daniela Aldrighetti, Franco Buzzi, Giorgio Cruciani, Antonio Farris, Giorgio Mustacchi, Mauro Porpiglia, Giorgio Schieppati, Piero Sismondi

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The superiority of new generation aromatase inhibitors over tamoxifen in the adjuvant treatment of early breast carcinoma has emerged from several randomized trials. However, until now not all previous studies have shown a mortality benefit. METHODS. A pooled analysis of 2 prospective multicentric trials, sharing the same study design and nearly identical inclusion criteria, was performed. In both trials, women treated previously with tamoxifen for 2 or 3 years were randomly assigned to either continuing tamoxifen for an additional 2 or 3 years or to having their treatment switched to aminoglutethimide or anastrozole for a comparable time period. Mortality was analyzed according to allocated treatment and other patient and tumor variables. RESULTS. In all, 828 postmenopausal women, mostly with estrogen receptor (ER)-positive and node-positive tumors who had been monitored for a median time of 78 months (range, 6-141 months) were analyzed. Of these women, 415 were randomly selected to continue tamoxifen and 413 switched to aminoglutethimide or anastrozole. All-cause mortality and breast cancer-specific mortality were significantly improved by the switch: all-cause mortality: hazard ratio (HR) = 0.61 (0.42-0.88) P = .007; breast cancer-specific mortality: HR = 0.61 (0.39-0.94) P =.025. No increase was recorded in breast cancer-unrelated mortality in women after switching. Multivariate analysis showed that patient age, tumor size, allocated treatment, and nodal status, in that order, were independent mortality predictors. CONCLUSIONS. Switching to an aromatase inhibitor after 2 or 3 years of tamoxifen therapy significantly improves survival compared with continuing 2 or 3 years of additional tamoxifen treatment.

Original languageEnglish
Pages (from-to)1060-1067
Number of pages8
JournalCancer
Volume109
Issue number6
DOIs
Publication statusPublished - Mar 15 2007

Keywords

  • Aromatase inhibitors
  • Early breast cancer
  • Mortality
  • Switching

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: Pooled analysis of 2 consecutive trials'. Together they form a unique fingerprint.

  • Cite this

    Boccardo, F., Rubagotti, A., Aldrighetti, D., Buzzi, F., Cruciani, G., Farris, A., Mustacchi, G., Porpiglia, M., Schieppati, G., & Sismondi, P. (2007). Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: Pooled analysis of 2 consecutive trials. Cancer, 109(6), 1060-1067. https://doi.org/10.1002/cncr.22513